Back to the Top
Thanks a lot for all the helpful answers I got. I still have some
confusions about the PK stuff I addressed last time. Since I didn't
provide enough details for my question, therefore, I would like to
readdress that PK question:
We conducted a very basic bioavailability study for a compound (one
iv dose 1-2 mg/kg, one oral study 40-50 mg/kg). Because the compound
is not very soluble, the dosing solution is kind of milky. Then it
comes to the result part. The compound is absorbed very fast (Tmax is
about 5min). Bioavailability of the compound is low, but the plasma
clearance of the compound is much less than the corresponding liver
blood flow. Both iv and po have biexponential decay. The terminal
t1/2 of iv is about 2-3 fold longer than oral. So, what do you guys
think the possible reasons could it be now?
Another quesion of mine is about bioavailability (I mean general
bioavailability for all compound). Most of the companies just use
the simple bioavailability or t1/2 to screen drug candidate. I
personaly don't think it should be that simple. So, could anyone give
some hints on this?
Thanks a lot.
Have a nice weekend.
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (email@example.com)